

The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product. Before prescribing any product mentioned in this Register, healthcare professionals should consult prescribing information for the product approved in their country.

Statement of Discontinuation of the study	
Name of Company: GlaxoSmithKline	
Study No: 116775 (EudraCT# 2013-004778-84)	
Product: GSK134612A	
Title : A Phase IIIb, open-label, multi-centric study to evaluate the immunogenicity of one dose of GSK Biologicals' MenACWY-TT conjugate vaccine administered intramuscularly in healthy adolescents aged 10 to 15 years, previously primed with a MenC conjugate vaccine.	
Phase: III	
Study Period: NA	
Centres: NA	
Number of Subjects: 0	
Publications: NA	
Statement on discontinuation of the study: Discontinued by GlaxoSmithKline during preparation of the trial. No patient entered the study, therefore no results / data are available.	